FDA Rejects Delcath Systems, Inc.'s Cancer Therapy, Fires CEO
Published: Sep 13, 2013
Delcath Systems Inc said the U.S. Food and Drug Administration rejected its cancer therapy, and asked for more trials, more than four months after a panel of U.S. advisers recommended against its approval. The company also said it fired Chief Executive Eamonn Hobbs on September 10 and appointed two interim co-CEOs. Further studies should show that the treatment is safe and effective based on overall survival, and that benefits outweigh risks, the FDA said.
Help employers find you! Check out all the jobs and post your resume.